9 stories mentioning WATUpdated 4d ago
Every FINWIRES story that references WAT, newest first.
Waters (WAT) has an average rating of overweight and mean price target of $402.47, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Waters (WAT) has an average rating of overweight and mean price target of $401.42, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $370.79, Change: $-7.37, Percent Change: -1.95%
Waters (WAT) has an average rating of overweight and mean price target of $399.10, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $346.32, Change: $+3.57, Percent Change: +1.04%
Waters (WAT) has an average rating of overweight and mean price target of $399.10, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $343.69, Change: $+1.16, Percent Change: +0.34%
US equity indexes ended higher on Tuesday after Defense Secretary Pete Hegseth said the ceasefire agreement with Iran remains in force and crude oil prices declined.* Hegseth, speaking at a press conference, promised to press ahead with opening the Strait of Hormuz, while Gen. Dan Caine, chairman of the Joint Chiefs of Staff, said Iran's military actions didn't rise to the level of restarting the war, according to the Wall Street Journal.* US job openings fell to 6.866 million in March from 6.922 million in February, according to the Bureau of Labor Statistics, versus the 6.85 million expected in a Bloomberg poll.* The Institute for Supply Management's US services index declined to 53.6 in April from 54.0 in March, versus expectations for 53.7 in a Bloomberg survey.* June West Texas Intermediate crude oil fell $3.71 to settle at $102.71 per barrel, while July Brent crude, the global benchmark, was last seen down $4.27 at $110.21.* Waters (WAT) shares rose 13%, the biggest gain on the S&P 500, after the company reported higher fiscal Q1 adjusted earnings and revenue.* Huntington Ingalls Industries (HII) shares fell 10%, the largest drop on the S&P, after the company's Q1 results.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $370 from $335, based on 25.5x our 2026 EPS estimate of $14.50 (up from $14.39; 2027 EPS down $0.05 to $16.34). This is a discount to WAT's three- and five-year historical forward P/E averages of 26.3x and 27.4x, respectively. We see ongoing weakness in academic/government end markets. We also note ongoing policy challenges in China, a key market for several U.S. life sciences tools and services firms, including headwinds for immunodiagnostics from China's diagnosis-related group reimbursement updates. While uncertainty remains regarding WAT's ability to fully realize anticipated synergies from the BDX deal, we view Q1 results as encouraging. The acquired Biosciences and Diagnostic Solutions businesses generated $520M in revenue since closing, $40M above guidance, representing a meaningful sequential improvement from Q4 2025. Of note, the Biosciences division saw just a 1% sales decline on a full-quarter pro forma basis, compared to a 10% decline in Q4 2025.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Waters Corporation reported Q1 adjusted EPS of $2.70 vs. $2.25, beating consensus by $0.39 (17%), while revenues of $1.267B topped guidance by $56M (4.6%). Organic business sales growth was 13% (11% constant currency), exceeding guidance by 200 bps, with Analytical Sciences delivering 14% growth to $607M. We think the quarter marks a successful start as a combined entity following the February 9 acquisition of BDX's Biosciences & Diagnostic Solutions business, supported by early realization of cross-division collaboration benefits and revenue synergies. Management raised full-year 2026 guidance across all key metrics, with organic constant currency growth guidance increased to 6.5%-8.0% from 5.5%-7.0% and adjusted EPS midpoint raised to $14.50 from $14.40. The acquired BDS businesses generated $520M in revenue since closing, $40M above guidance, while geographically Asia sales fell to 28% of total revenue vs. 33% in the prior year as Europe rose to 33% from 28%.
Health care stocks were higher premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining by 0.1% and the iShares Biotechnology ETF (IBB) advancing 0.2%.IDEXX Laboratories (IDXX) shares rose more than 3% pre-bell after the company reported higher Q1 comparable earnings and revenue.Waters (WAT) shares were over 10% higher pre-bell after the company reported higher fiscal Q1 adjusted earnings and revenue.Fresenius Medical Care (FMS) stock was down more than 5% premarket after the company reported lower Q1 earnings and revenue.
Waters (WAT) has an average rating of overweight and mean price target of $387.24, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $317.55, Change: $-2.45, Percent Change: -0.77%
